Hansa Medical strengthens its liquidity
”We have secured this credit in order to concentrate entirely on the finalisation and reporting of the ongoing clinical Phase I study of IdeS. The Phase I study was initiated in March 2013 and our goal is to complete this study during the current year. We will, thereafter, aim at initiating the exciting Phase II study during the spring of 2014”, states Emanuel Björne, CEO of Hansa Medical AB.
Highly sensitized renal transplant patients
There are many requirements for a patient to actually be able to undergo a kidney transplant. The patients on the transplant wait lists include a sub-group of patients comprised of highly sensitized transplant patients. These patients’ immune systems are characterised by high levels of reactive antibodies significantly reducing the body’s possibility to receive a donated, healthy organ. A vast majority of these patients have to spend significantly longer time waiting for a transplant.
The drug candidate IdeS
The drug candidate IdeS inactivates antibodies immediately prior to a kidney transplant and, in this manner, removes this particular obstacle to transplantation. The goal is to be able to treat approximately 5,000 patients a year in the US and Europe, at a total value of slightly more than one billion SEK.